Erythropoietin use in critically ill patients: forest and trees.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Low serum erythropoietin levels are associated with fatal COVID-19 cases at 4,150 meters above sea level.Respiratory physiology & neurobiology · 2021
   Observational
2. The association of erythropoietin-stimulating agents and increased risk for AV-fistula dysfunction in hemodialysis patients. A retrospective analysis.BMC nephrology · 2021
   Observational
3. Erythropoietin reduces acute lung injury and multiple organ failure/dysfunction associated to a scald-burn inflammatory injury in the rat.Inflammation · 2015
   Article
4. Anemia and blood transfusions in critically ill patients.Journal of blood transfusion · 2012
   Review
5. The role of erythropoietin as an inhibitor of tissue ischemia.International journal of biological sciences · 2008
   Review

Corrections and comments

• Comment on
  Erythropoietin-receptor agonists in critically ill patients: a meta-analysis of randomized controlled trials.2007

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as